Recent months have seen a slew of management changes at major generics companies. Some of this has been driven by shareholder dissatisfaction with poor performance (Teva being the obvious example here), but there have also been generational and other shifts that offer interesting pointers...
Hero or zero? Kåre Schultz proposes rational solutions in an irrational market
Teva’s new CEO, Kåre Schultz, has now been in place for just over three months, and at the end of last year, he laid out his plans to deal with Teva’s immediate problems of excessive debt and sliding profitability. The main highlight was massive...